Skip to main content
NeuroThera Labs Inc. logo

NeuroThera Labs Inc. — Investor Relations & Filings

Ticker · NTLX ISIN · CA64136J1012 LEI · 529900GPL3C0DVADMS32 TSXV Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2026-03-11 Regulatory Filings
Country CA Canada
Listing TSXV NTLX

About NeuroThera Labs Inc.

https://www.neurothera.com/

NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-03-11 English
News release - English.pdf
Regulatory Filings
2026-03-10 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2026-02-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Neurothera Labs Inc. announcing the granting of a U.S. patent for its cannabinoid-based antimicrobial technology. It follows the standard format of a corporate press release, including a headline, dateline, company description, and contact information. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2026-02-02 English
Notice.pdf
AGM Information Classification · 98% confidence The document is titled 'NOTICE ANNUELLE' (Annual Information Form) for Transcontinental inc., covering the fiscal year ended October 26, 2025. It contains detailed sections on company structure, business activities, capital structure, management, and audit committee information. This document is a standard Canadian regulatory filing known as an Annual Information Form (AIF), which provides comprehensive annual information about the company's business and operations, distinct from the audited financial statements themselves. In the provided taxonomy, '10-K' is the closest equivalent for a comprehensive annual report/filing of this nature.
2026-01-22 French
Letter from successor auditor.pdf
Audit Report / Information Classification · 95% confidence The document is a formal letter from an auditing firm (Deloitte/Brightman Almagor Zohar & Co.) addressed to various Canadian Securities Commissions regarding a 'Notice of Change of Auditor' for Neurothera Labs Inc. pursuant to National Instrument 51-102. This is a regulatory filing concerning corporate governance and auditor relations, which does not fit into specific categories like financial reports or earnings releases. Therefore, it is classified as a Regulatory Filing (RNS). FY 2026
2026-01-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.